Factors associated with the prescription of "traditional" or "biological" systemic treatment in psoriasis

Stefano Tabolli, Andrea Paradisi, Patrizia Giannantoni, Emanuela Gubinelli, Damiano Abeni

Research output: Contribution to journalArticlepeer-review


The choice of an adequate psoriasis treatment is critical to good disease management and to overall patient health. It is estimated that about 20-30% of patients requires systemic treatment: "traditional" (methotrexate, acitretina and cyclosporin) or "biological" (etanercept, adalimumab and infliximab). Clinical records of 784 outpatients with psoriasis were analyzed. 51.5% received traditional treatments and 48.5% a biological treatment. Males were 67.8% of patients. Psoriatic arthritis was observed in 37.3%. Females and younger patients were more likely to receive biological treatments. No differences were observed for Body Mass Index or for presence of comorbidities. Patients with psoriatic arthritis were also more frequently prescribed biological drug treatment. In a multivariate logistic regression model, only the older age-group (≥60 years) had a statistically significant OR (p=0.001) with a reduction of about 80% the likelihood of receiving biological treatment compared to the younger age-group (

Original languageEnglish
Pages (from-to)37-40
Number of pages4
JournalJournal of Dermatological Treatment
Issue number1
Publication statusPublished - Feb 1 2015


  • Biologics
  • Psoriasis
  • Systemic treatment
  • Traditional

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Factors associated with the prescription of "traditional" or "biological" systemic treatment in psoriasis'. Together they form a unique fingerprint.

Cite this